# Cardiox Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cardiox

- Industry: Medical Devices & Equipment
- Headquarters: Columbus, US
- Website: www.cardiox.com
- Total disclosed funding: $12M
- Latest round: Series D (Apr 4, 2014)
- Investors on record: 4

## About

Cardiox Corporation specializes in advanced cardiovascular monitoring technology through its innovative Cardio X platform, which offers integrated biosensing capabilities for health and fitness applications.Established in 1996 and headquartered in Columbus, US, Cardiox Corporation develops advanced monitoring solutions for cardiovascular health. Founded by Phillip Edgars, the company has secured a total of USD 3.16 mn in funding, with its latest round in April 2014, supported by Early Stage Partners and Reservoir Venture Partners. Cardiox has executed 9 total deals to date and focuses on delivering AI-driven health insights through its platform, Cardio X.Cardiox specializes in advanced cardiovascular monitoring with its core product, Cardio X, an AI-powered biosensing platform. This system combines multiple sensing modalities, such as electrocardiogram and photoplethysmography, into a compact, wearable device. Cardio X is designed for various applications, providing real-time physiological insights for sports teams, healthcare providers, researchers, and wellness professionals. This platform enhances health tracking and offers actionable data for optimizing athletic performance, managing patient recovery, and conducting health studies across North America, Europe, and the Middle East.Cardiox generates revenue through strategic partnerships and pilot programs in healthcare, fitness, and research sectors. The company employs subscription models or one-time fees for access to the Cardio X platform, which includes comprehensive health-tracking and data analytics tools. Clients, including fitness centers and healthcare providers, typically enter long-term agreements for ongoing monitoring and support, along with setup services and customized data reporting tailored to their needs. Cardio X plays a critical role in these agreements by providing enhanced performance metrics and clinical-grade insights.Looking ahead, Cardiox Corporation plans to leverage its recent funding of USD 3.16 mn raised in April 2014 to enhance the Cardio X platform and explore new product features. The company aims to expand its market presence in Europe and the Middle East by 2025, collaborating with additional organizations in healthcare and fitness. This strategic expansion is aimed at increasing user engagement and broadening the application of the Cardio X system in various health and wellness initiatives.

## Funding rounds

- Series D, Apr 4, 2014, $3.2M — Early Stage Partners, Reservoir Venture Partners
- Series C, Dec 28, 2012, $0.4M — Early Stage Partners
- Series C, Aug 29, 2011, $8M — Early Stage Partners, Reservoir Venture Partners, Glengary, Lifeline Ventures

## Investors

- Early Stage Partners (https://capitalatlas.ai/funds/early-stage-partners) — Series C, Series D
- Reservoir Venture Partners (https://capitalatlas.ai/funds/reservoir-venture-partners) — Series C, Series D
- Glengary (https://capitalatlas.ai/funds/glengary) — Series C
- Lifeline Ventures (https://capitalatlas.ai/funds/lifeline-ventures) — Series C